Gain of HIF-1α under normoxia in cancer mediates immune adaptation through the AKT/ERK and VEGFA axes

Clinical Cancer Research

Volumn 21, Issue 6, 2015, Pages 1438-1446

  Lee, Young Ho ^a   Bae, Hyun Cheol ^a   Noh, Kyung Hee ^a   Song, Kwon Ho ^a   Ye, Sang Kyu ^b   Mao, Chih Ping ^c   Lee, Kyung Mi ^a   Wu, T C ^c   Kim, Tae Woo ^a  

^a Korea University College of Medicine   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; VASCULOTROPIN A; HIF1A PROTEIN, HUMAN; OXYGEN; VEGFA PROTEIN, HUMAN;

ADAPTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BLOOD OXYGENATION; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PATIENT; CARCINOGENESIS; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; GENE EXPRESSION; IMMUNE ADAPTATION; IMMUNITY; IMMUNOSURVEILLANCE; MOUSE; NATURAL HOST; NEOPLASM; NONHUMAN; NORMOXIA; OXYGEN TENSION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SIMULATION; TUMOR CELL; VACCINATION; ANIMAL; C57BL MOUSE; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; TUMOR CELL LINE; TUMOR ESCAPE;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; MICE, INBRED C57BL; NEOPLASMS; OXYGEN; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TUMOR ESCAPE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84927665956     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-1979     Document Type: Article

References (25)

1. Greaves M, Maley CC. Clonal evolution in cancer. Nature 2002;481:306.
2. Semenza GL. Targeting HIF1 for cancer therapy. Nat Rev Cancer 2003;3:721.
3. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 1999; 59:5830.
4. Barsoum IB, Hamilton TK, Li X, Cotechini T, Miles EA, Siemens DR, et al. Hypoxia induces escape from innate immunity in cancer cells via increased expression of ADAM10: role of nitric oxide. Cancer Res 2011;71:7433.
5. Barsoum IB, Smallwood CA, Siemens DR, Graham CH. A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells. Cancer Res 2014;74:665.
6. Noman MZ, Buart S, Van Pelt J, Richon C, Hasmim M, Leleu N, Chouaib S. The cooperative induction of hypoxia-inducible factor-1 alpha and STAT3 during hypoxia induced an impairment of tumor susceptibility to CTL-mediated cell lysis. J Immunol 2009;182;3510.
7. Noman MZ, Janji B, Kaminska B, VanMoer K, Pierson S, Przanowski P, Chouaib S. Blocking hypoxia-induced autophagy in tumors restores cytotoxic T-cell activity and promotes regression. Cancer Res 2011; 71;5976.
8. Hasmim M, Noman MZ, Lauriol J, Benlalam H, Mallavialle A, Rosselli F, Chouaib S. Hypoxia-dependent inhibition of tumor cell susceptibility to CTL-mediated lysis involves NANOG induction in target cells. J Immunol 2011;187;4031.
9. Noman MZ, Buart S, Romero P, Ketari S, Janji B, Chouaib S. Hypoxia-inducible miR-210 regulates the susceptibility of tumor cells to lysis by cytotoxic T cells. Cancer Res 2012;72;4629.
10. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999;399:271.
11. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011;331:1565.
12. Lin KY, Lu D, Hung CF, Peng S, Huang L, Jie C, et al. Ectopic expression of vascular cell adhesion molecule-1 as a new mechanism for tumor immune evasion. Cancer Res 2007;67:1832.
13. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, Levitsky HI, August JT, Pardoll DM, et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996;56:21.
14. Noh KH, Kang TH, Kim JH, Pai SI, Lin KY, Hung CF, et al. Activation of Akt as a mechanism for tumor immune evasion. Mol Ther 2009;17:439.
15. Noh KH, Lee YH, Jeon JH, Kang TH, Mao CP, Wu TC, et al. Cancer vaccination drives Nanog-dependent evolution of tumor cells toward an immune-resistant and stem-like phenotype. Cancer Res 2012;72:1717.
16. Wu TC, Guarnieri FG, Staveley-O'Carroll KF, Viscidi RP, Levitsky HI, Hedrick L, et al. Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc Natl Acad Sci USA 1995;92:11671.
17. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996;16:4604.
18. Pidgeon GP, Barr MP, Harmey JH, Foley DA, Bouchier-Hayes DJ. Vascular endothelial growth factor (VEGF) upregulates BCL-2 and inhibits apoptosis in human and murine mammary adenocarcinoma cells. Br J Cancer 2001;20:273.
19. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004;22:329.
20. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2001;29:235.
21. DuPage M, Mazumdar C, Schmidt LM, Cheung AF, Jacks T. Expression of tumour-speci fic antigens underlies cancer immunoediting. Nature 2012; 482:405.
22. Igney FH, Krammer PH. Immune escape of tumors: apoptosis resistance and tumor counterattack. J Leukoc Biol 2002;71:907-920.
23. Birner P, Preusser M, Gelpi E, Berger J, Gatterbauer B, Hainfellner JA. Expression of hypoxia-related tissue factors correlates with diminished survival of adjuvantly treated patients with chromosome 1p aberrant oligodendroglial neoplasms and therapeutic implications. Clin Cancer Res 2004;10:6567.
24. HelmlingerG, Yuan F,Dellian M, Jain RK. Interstitial pHand pO2 gradients in solid tumors in vivo : high-resolution measurements reveal a lack of correlation. Nat Med 1997;3:177-82.
25. Manjili MH. The adaptation model of immunity. Immunotherapy 2014;6:59.